<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066594</url>
  </required_header>
  <id_info>
    <org_study_id>TIF REGISTRY 2021</org_study_id>
    <nct_id>NCT05066594</nct_id>
  </id_info>
  <brief_title>Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)</brief_title>
  <acronym>TIF/2021</acronym>
  <official_title>Observational Registry of Transoral Incisionless Fundoplication (Creation of a New Gastroesophageal Valve) in Patients With Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational registry aims to: 1) record the TIF interventions in patients with&#xD;
      esophageal or extra-esophageal symptoms; 2) to monitor the therapy response through the&#xD;
      clinical experience in terms of effect on the use and dosage of proton pump inhibitors (PPIs)&#xD;
      and on the GERD-Health Related Quality of Life (HRQL) and Reflux Symptom Index (RSI)&#xD;
      questionnaires scores; 3) to characterize the treated patients population and the predictive&#xD;
      factors of TIF success, identifying the subpopulation who may effectively benefit from TIF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being evaluated according to the clinical indication for the treatment of symptomatic&#xD;
      gastro-esophageal reflux disease (GERD with esophageal or extraesophageal symptoms) by&#xD;
      transoral incisionless fundoplication (TIF) and, thus, being treated by TIF using the EsophyX&#xD;
      device, all patients giving specific informed consent will enter a 3-year enrollment registry&#xD;
      with a 5-year follow-up for each patient through post-TIF routine practice visits and&#xD;
      examinations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 2029</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Medical use and dosage</measure>
    <time_frame>Yearly, up to 5 years from the date of the intervention</time_frame>
    <description>Need to use proton pump inhibitors (PPI), and at what dosage, to control the gastro-esophageal reflux symptoms after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life questionnaire score</measure>
    <time_frame>Yearly, up to 5 years from the date of the intervention</time_frame>
    <description>Modification of the scores from the gastro-esophageal reflux disease-health related quality of life (GERD-HRQL) questionnaire (off proton pump inhibitors), according to a Likert scale from 0 (absence of symptoms) to 5 (symptoms do not allow for normal daily activity), after intervention compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reflux Symptom Index questionnaire score</measure>
    <time_frame>Yearly, up to 5 years from the date of the intervention</time_frame>
    <description>Modification of the scores from the reflux symptom index (GERD-RSI) questionnaire (off proton pump inhibitors), according to a Likert scale from 0 (no problem) to 5 (severe problem) after the intervention compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Esophagitis</measure>
    <time_frame>6 months and 12 months after the date of the intervention</time_frame>
    <description>Presence and degree of esophagitis according to the Los Angeles classification (grade A, grade B, grade C, grade D) after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hill's grade of the gastro-esophageal flap valve</measure>
    <time_frame>6 months and 12 months after the date of the intervention</time_frame>
    <description>Degree of continence of the neo gastro-esophageal flap valve according to the Hill classification (grade I, grade II, grade III, grade IV) after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Jobe's length of the gastro-esophageal valve</measure>
    <time_frame>6 months and 12 months after the date of the intervention</time_frame>
    <description>Length of the fold of the neo gastro-esophageal valve according to the criteria of Jobe et al. after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barrett's esophagus</measure>
    <time_frame>6 months and 12 months after the date of the intervention</time_frame>
    <description>Presence and degree of Barrett's esophagus according to the Prague classification (C, M) after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-resolution esophageal manometry findings</measure>
    <time_frame>12 months after the date of the intervention</time_frame>
    <description>Esophageal manometry measurements after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour esophageal pH-metry findings</measure>
    <time_frame>12 months and 24 months after the date of the intervention</time_frame>
    <description>24-hour esophageal pH-metry measurements off proton pump inhibitors after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour esophageal impedancemetry findings</measure>
    <time_frame>12 months and 24 months after the date of the intervention</time_frame>
    <description>24-hour esophageal pH-impedance measurements off proton pump inhibitors after the intervention</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastro Esophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Transoral incisionless fundoplication with EsophyX device (EndoGastric Solutions)</arm_group_label>
    <description>Patients treated by transoral incisionless fundoplication (TIF) using the EsophyX device (EndoGastric Solutions) for gastro-esophageal reflux disease will be enrolled in the registry and clinically followed-up for 5 years from the date of TIF procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transoral incisionless fundoplication</intervention_name>
    <description>The intervention of transoral incisionless fundoplication using the EsophyX (EndoGastric Solutions) system allows, through the endoscopic route, the creation of a cardial neovalve of approximately 270 ° by placing 20-28 polyethylene sutures on the cardial circumference, resulting in an anti-reflux plastic functionally similar to that obtained with the surgical fundoplication.</description>
    <arm_group_label>Transoral incisionless fundoplication with EsophyX device (EndoGastric Solutions)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion criteria for TIF: &gt;12 months esophageal or extraesophageal symptoms from&#xD;
        gastroesophageal reflux, despite &gt;6 months therapy with PPI; cardial valve Hill's degree&#xD;
        &gt;III; pathological gastroesophageal reflux; hiatal hernia ≤2 cm.&#xD;
&#xD;
        Exclusion criteria for TIF: hiatal hernia &gt;2 cm; paraesophageal hernia; severe esophageal&#xD;
        motility disorder or Los Angeles grade C and D esophagitis; esophageal stenosis,&#xD;
        diverticula, infections; pregnancy, breastfeeding; bleeding disorders; malignant neoplasm;&#xD;
        immunosuppressant therapy; portal hypertension; esophageal varices; eosinophilic&#xD;
        esophagitis; autoimmune esophagitis; BMI ≥35; limited mobility of the neck; patients for&#xD;
        whom the use of the EsophyX device is contraindicated.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for enrollment:&#xD;
&#xD;
          -  Clinical indication to undergo transoral incisionless fundoplication (TIF) with the&#xD;
             EsophyX device for treatment of chronic gastro-esophageal reflux disease;&#xD;
&#xD;
          -  Availability for prolonged follow-up (5 years) after TIF at San Raffaele Hospital;&#xD;
&#xD;
          -  Signed informed consent for participation in the observational registry.&#xD;
&#xD;
        Exclusion Criteria for enrollment:&#xD;
&#xD;
          -  Absence of clinical indication to undergo transoral incisionless fundoplication (TIF)&#xD;
             with the EsophyX device for treatment of chronic gastro-esophageal reflux disease;&#xD;
&#xD;
          -  Unavailability for prolonged follow-up (5 years) after TIF at San Raffaele Hospital;&#xD;
&#xD;
          -  No signed informed consent for participation in the observational registry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pier Alberto Testoni, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pier Alberto Testoni, MD, Prof.</last_name>
    <phone>+39 02/26432756</phone>
    <email>testoni.pieralberto@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabrina Gloria Giulia Testoni, MD, PhD</last_name>
    <phone>+39 02/26436303</phone>
    <email>testoni.sabrinagloriagiulia@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pier Alberto Testoni, MD, Prof.</last_name>
      <phone>+39 02/26432756</phone>
      <email>testoni.pieralberto@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Sabrina Gloria Giulia Testoni, MD, PhD</last_name>
      <phone>+39 02/26436303</phone>
      <email>testoni.sabrinagloriagiulia@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Pier Alberto Testoni, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabrina Gloria Giulia Testoni, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandro Passaretti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuela Ribichini, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Pier Alberto Testoni</investigator_full_name>
    <investigator_title>Head of Gastroenterology and Digestive Endoscopy</investigator_title>
  </responsible_party>
  <keyword>Fundoplication</keyword>
  <keyword>Endoscopy, Digestive System</keyword>
  <keyword>Gastro Esophageal Reflux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

